Fulcrum therapeutics to participate at upcoming november investor conferences

Cambridge, mass., nov. 09, 2023 (globe newswire) -- fulcrum therapeutics, inc.® (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following upcoming investor conferences:
FULC Ratings Summary
FULC Quant Ranking